

Thomas C. Lenzmeier, M.D.
CCT Research
1910 S Stapley Drive, Suite 120
Mesa, AZ 85204

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, VP Sponsor Relations/BD
Apex Innovative Sciences, Alliance Division
Tel. 916-803-7149 (cell)
Email: bobbietheodore@apexsci.com

AFFILIATIONS:

Thomas C. Lenzmeier, MD, PC/CCT Research
20100 N 51st Avenue, Suite F630
Glendale, AZ 85308

EDUCATION:

1996 M.D.
 University of Minnesota School of Medicine, Minneapolis, Minnesota

1992 B.S. - Bioengineering
 Arizona State University School of Engineering, Tempe, Arizona

RESIDENCY:

1996-1999 Family Medicine
 Phoenix Baptist Family Medicine, Phoenix, Arizona

LICENSURE:

Arizona MD License Number: 25528

PROFESSIONAL MEMBERSHIPS:

1999 – American Board of Family Medicine, Certified
1996 – American Academy of Family Physicians

PROFESSIONAL EXPERIENCE:

Principal Investigator, 2019 – Present
CCT Research, Scottsdale, AZ

PROFESSIONAL EXPERIENCE (*continued*):

Principal Investigator, 2013 – 2019

Accelerated Enrollment Solutions (formerly Synexus), Glendale, Arizona

President, Physician, 2010 – Present

Thomas C. Lenzmeier, M.D., PC, Glendale, Arizona

Physician, 1999 – 2010

Westside Family Practice, Glendale, Arizona

INVESTIGATOR EXPERIENCE:

Cardiovascular Disease • COPD • COVID treatment studies • Hypertriglyceridemia • Influenza
Irritable Bowel Syndrome • Migraine • Men’s Health • Mild Cognitive Deficits
Neuropathic Pain • Obesity • Osteoarthritis • Pain • Rheumatoid Arthritis • Type 2 Diabetes

ADDITIONAL INTEREST:

Allergy • Cardiology • Collection Studies • Dermatology • Devices
Diagnostic Studies – COVID • Endocrinology • Gastroenterology • Geriatrics • Immunology
Infectious Disease • Metabolic • Nutrition • Nephrology • Orthopedics
Oncology (Diagnostic studies and cancer pain) • Pulmonology • Rheumatology • Urology
Vaccines (COVID and other)

CLINICAL TRIAL EXPERIENCE:

Arthritis

Study To Evaluate Arthroplasty Specimens In The Phase III XXX Program For Osteoarthritis Of The Knee And Hip

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Effects Of XXX On Peripheral Nerve Function In Patients With Pain Due To Osteoarthritis Of The Hip Or Knee

A Phase III Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study To Evaluate The Long-Term Safety And The Efficacy Of XXX In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip

A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing XXX With Naproxen And Ibuprofen

CLINICAL TRIAL EXPERIENCE (*continued*):

COPD

Expansion Of Interpretation Guidelines For The COPD Assessment Test (CAT), Level Of Impact Scores In Primary Care Centers In The US

COVID-19

A Phase II, Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of XXX in Adults With Mild COVID-19 Symptoms

Diabetes

Efficacy And Safety Of XXX Once-Weekly Versus Placebo As Add-On To SGLT-2i In Subjects With Type 2 Diabetes Mellitus.

Efficacy And Safety Of XXX Versus Placebo In Subjects With Type 2 Diabetes Mellitus Treated With Insulin

A Trial Comparing The Efficacy And Safety Of XXX And XXX In Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With Or Without Oral Antidiabetic Drugs

A Phase Ib, Randomised, Parallel, Double-Blind Placebo-Controlled And Open-Label Active Comparator Study To Evaluate The Efficacy And Safety Of XXX In The Treatment Of Overweight And Obese Subjects With Type 2 Diabetes Mellitus

A Phase IIIb, Randomized, Active Comparator, Open-Label, Multicenter Study To Compare The Efficacy, Safety, And Tolerability Of XXX To XXX And To XXX As Add-On Therapy To Metformin In Patients With Type 2 Diabetes

Efficacy And Long-Term Safety Of Oral XXX Versus XXX As Add-On To 1- 2 Oral Antidiabetic Drugs (OAD)S In Subjects With Type 2 Diabetes

A 104 Week Clinical Trial Comparing Long Term Glycemic Control XXX Versus Insulin Glargine Therapy In Subjects With Type 2 Diabetes Mellitus

A Clinical Trial Comparing Glycemic Control And Safety Of XXX Versus Insulin Glargine (Iglar) As Add-On Therapy To SGLT2i In Subjects With Type 2 Diabetes Mellitus

A Randomized, Open-Label, Parallel-Group Real World Pragmatic Trial To Assess The Clinical And Health Outcomes Of XXX Compared To Commercially Available Basal Insulins For Initiation Of Therapy In Insulin Naive Patients With Uncontrolled Type 2 Diabetes Mellitus

CLINICAL TRIAL EXPERIENCE (*continued*):

A Long Term, Randomized, Double Blind, Placebo-Controlled Study To Determine The Effect Of XXX, When Added To Standard Blood Glucose Lowering Therapies, On Major Cardiovascular Events In Patients With Type 2 Diabetes Mellitus

A Trial Comparing Cardiovascular Safety Of XXX Versus XXX In Subjects With Type 2 Diabetes At High Risk Of Cardiovascular Events

A Randomized, Multicenter Study To Evaluate Cardiovascular Outcomes With XXX In Patients Treated With Standard Of Care For Type 2 Diabetes

A Clinical Trial Comparing Efficacy And Safety Of Insulin XXX In Subjects With Type 2 Diabetes Mellitus, When Titrated Using Two Different Titration Algorithms

Hypertriglyceridemia

A Phase III, Double-Blind, Long-Term Outcomes Study to Assess Statin Residual Risk Reduction with XXX in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH)

Influenza

A Multicenter Study Conducted to Evaluate the Performance of the XXX Flu A&B Assay at Point of Care Testing Sites

A Randomized Double-Blind Phase II Study Comparing the Efficacy, Safety, And Tolerability of Combination Antivirals XXX Versus XXX for The Treatment of Influenza in Adults At Risk For Complications.

A Randomized Double-Blind Phase II Study Comparing the Efficacy, Safety, And Tolerability of Combination Antivirals (XXX, XXX, XXX) Versus XXX for The Treatment of Influenza in Adults At Risk For Complications

Irritable Bowel Syndrome

A 52-Week, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Phase III Study With Re- Randomisation At Weeks 25 To Evaluate The Efficacy And Safety Of XXX L 0 Mg Once Daily In Female Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Migraine

A Study of two Doses Of XXX Compared To Placebo In The Acute Treatment Of Migraine: A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study (Samurai)

An Open-Label Long Term Safety Study Of XXX In The Acute Treatment Of Migraine

CLINICAL TRIAL EXPERIENCE (*continued*):

Pain

A Phase II, Randomized, Double-blind, Placebo and Active Comparator-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of XXX in the Treatment of Diabetic Peripheral Neuropathic Pain

A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Phase III Study To Evaluate The Efficacy And Safety Of XXX In Patients With Moderate To Severe Chronic Low Back Pain

Other Indications

A Longitudinal Study Of XXX In An Average Risk Population Assessing A Three Year Test Interval

A Longitudinal Study Of XXX In An Average Risk Population Assessing A Three Year Test Interval

A Validation Study Of The Novel Application Of Telehealth In Clinical Drug Development In Subjects With Mild Cognitive Deficits

A Phase IV, Testosterone Replacement Therapy For Assessment Of Long-Term Vascular Events And Efficacy Response In Hypogonadal Men (TRAVERSE) Study

A Randomized, Double-Blind, Placebo-Controlled Study To Assess The Effects Of XXX On The Occurrence Of Major Cardiovascular Events In Patients With, Or At High Risk For, Cardiovascular Disease Who Are Statin Intolerant

XXX Effects On Cardiovascular Outcomes In People With Overweight Or Obesity